| Drug Name: | Pyridoxine (65-23-6) |
|---|---|
| PubChem ID: | 1054 |
| SMILES: | CC1=NC=C(C(=C1O)CO)CO |
| InchiKey: | LXNHXLLTXMVWPM-UHFFFAOYSA-N |
| Therapeutic Category: | Growth Substances, Micronutrients, Vitamin B Complex, Vitamins |
| Molecular Weight (dalton) | : | 169.18 |
| LogP | : | 0.08022 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 4 |
| Hydrogen Bond Donor Count | : | 3 |
| Total Polar Surface Area | : | 73.58 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Phenobarbital (50-06-6) | Reduced Phenobarbital Serum Levels | Antagonistic | pyridoxine increases the activity of the liver enzymes concerned with the metabolism of these antiepileptics | Pyridoxine and serum concentration of phenytoin and phenobarbitone |
| Levodopa (59-92-7) | Effects Of Levodopa Are Reduced | Antagonistic | The conversion of levodopa to dopamine within the body requires the presence of pyridoxal-5-phosphate (derived from pyridoxine) as a co-factor. When dietary amounts of pyridoxine are high, the peripheral metabolism of levodopa by dopa-decarboxylase is increased so that less is available for entry into the CNS | Pyridoxine reversal of L-dopa effects in Parkinsonism |
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category